Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)

This article has no abstract
Epistemonikos ID: 294ba22d33abcdde3acf4ba25c89a7672e6071dc
First added on: Feb 17, 2025